Changes in Hong Kong stocks | Baoji Pharmaceutical-B (02659) rose more than 15% in the intraday period, BJ044 is expected to form a systematic replacement for existing urine extraction products

The Zhitong Finance App learned that Baoji Pharmaceutical-B (02659) rose more than 15% in the intraday period. As of press release, it had risen 10.97% to HK$21.14, with a turnover of HK$62.383 million.

According to the news, Baoji Pharmaceutical recently announced that the self-developed BJ044 injection (recombinant urastatin) clinical trial application (IND) has been officially approved by the National Drug Administration (NMPA). BJ044 is the world's first recombinant urastatin product developed through synthetic biology technology.

Notably, BJ044 is expected to be a systematic replacement for existing urine source extraction products with the comprehensive advantages of purity, safety, consistency and cost efficiency. Analysts pointed out that for Baoji Pharmaceutical, the IND approval of BJ044 is another verification of the technical strength of its synthetic biology platform. It is also another key point for the company to realize pipeline value after SJ02 and KJ017.